Emerging nanotechnology backed formulations for the management of atopic dermatitis
Atopic dermatitis is a prevalent chronic skin inflammation affecting 2.1 to 4.1% of adults globally. The complexity of its pathogenesis and the relapsing nature make it challenging to treat. Current treatments follow European Academy of Dermatology and Venerology guidelines, but advanced cases with recurring lesions lack effective therapies. To address this gap, researchers are exploring nanotechnology for targeted drug delivery. Nanoparticles offer benefits such as improved drug retention, stability, controlled release and targeted delivery through the disrupted epidermal barrier. This integrated review evaluates the current state of AD treatment and highlights the potential of novel nano-formulations as a promising approach to address the disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 14(2023), 9 vom: 01. Sept., Seite 543-569 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mahato, Ranjit Kumar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atopic dermatitis |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 09.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2023-0033 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361692218 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361692218 | ||
| 003 | DE-627 | ||
| 005 | 20240209231926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2023-0033 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1285.xml |
| 035 | |a (DE-627)NLM361692218 | ||
| 035 | |a (NLM)37671556 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mahato, Ranjit Kumar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging nanotechnology backed formulations for the management of atopic dermatitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 09.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Atopic dermatitis is a prevalent chronic skin inflammation affecting 2.1 to 4.1% of adults globally. The complexity of its pathogenesis and the relapsing nature make it challenging to treat. Current treatments follow European Academy of Dermatology and Venerology guidelines, but advanced cases with recurring lesions lack effective therapies. To address this gap, researchers are exploring nanotechnology for targeted drug delivery. Nanoparticles offer benefits such as improved drug retention, stability, controlled release and targeted delivery through the disrupted epidermal barrier. This integrated review evaluates the current state of AD treatment and highlights the potential of novel nano-formulations as a promising approach to address the disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a atopic dermatitis | |
| 650 | 4 | |a dermal toxicity | |
| 650 | 4 | |a drug targeting nanoformulations | |
| 650 | 4 | |a epidermal disruption | |
| 650 | 4 | |a pruritus | |
| 700 | 1 | |a Singh, Mohini |e verfasserin |4 aut | |
| 700 | 1 | |a Pathak, Hemanta |e verfasserin |4 aut | |
| 700 | 1 | |a Gogoi, Niva Rani |e verfasserin |4 aut | |
| 700 | 1 | |a Kharbithai, Rikynjai |e verfasserin |4 aut | |
| 700 | 1 | |a Chowrasia, Pinky |e verfasserin |4 aut | |
| 700 | 1 | |a Bora, Pankaj Lochan |e verfasserin |4 aut | |
| 700 | 1 | |a Sarkar, Tumpa |e verfasserin |4 aut | |
| 700 | 1 | |a Jana, Bani Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Mazumder, Bhaskar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 14(2023), 9 vom: 01. Sept., Seite 543-569 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:9 |g day:01 |g month:09 |g pages:543-569 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2023-0033 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 9 |b 01 |c 09 |h 543-569 | ||